Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.
OBJECTIVE
To investigate whether selective serotonin reuptake inhibitor (SSRI) antidepressants are associated with an increased risk of suicide related outcomes in adults.


METHODS
Meta-analysis of randomised controlled trials of SSRIs compared with placebo in adults submitted by pharmaceutical companies to the safety review of the Medicines and Healthcare products Regulatory Agency (MHRA).


METHODS
Over 40,000 individuals participating in 477 randomised controlled trials.


METHODS
Suicide, non-fatal self harm, and suicidal thoughts.


RESULTS
An estimated 16 suicides, 172 episodes of non-fatal self harm, and 177 episodes of suicidal thoughts were reported. We found no evidence that SSRIs increased the risk of suicide, but important protective or hazardous effects cannot be excluded (odds ratio 0.85, 95% credible interval 0.20 to 3.40). We found weak evidence of an increased risk of self harm (1.57, 0.99 to 2.55). Risk estimates for suicidal thoughts were compatible with a modest protective or adverse effect (0.77, 0.37 to 1.55). The relative frequency of reported self harm and suicidal thoughts in the trials compared with suicide indicates non-fatal end points were under-recorded.


CONCLUSIONS
Increased risks of suicide and self harm caused by SSRIs cannot be ruled out, but larger trials with longer follow up are required to assess the balance of risks and benefits fully. Any such risks should be balanced against the effectiveness of SSRIs in treating depression. When prescribing SSRIs, clinicians should warn patients of the possible risk of suicidal behaviour and monitor patients closely in the early stages of treatment.
Gunnell
David
D
Department of Social Medicine, University of Bristol, Bristol BS8 2PR. D.J.Gunnell@bristol.ac.uk
Saperia
Julia
J
Ashby
Deborah
D
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016728:Self-Injurious Behavior / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013405:Suicide / Q000706:statistics & numerical data*
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors
J Psychopharmacol. 1999;13(1):94-9
10221363
Am J Psychiatry. 2003 Apr;160(4):790-2
12668373
BMJ. 1998 Nov 7;317(7168):1309-12
9804726
JAMA. 2003 Aug 20;290(7):921-8
12928469
JAMA. 2004 Jul 21;292(3):338-43
15265848
Lancet. 2004 Apr 24;363(9418):1341-5
15110490
BMJ. 2004 Jul 3;329(7456):34-8
15231620
BMJ. 1991 Sep 21;303(6804):685-92
1833012
BMJ. 1995 Jan 28;310(6974):215-8
7677826
Popul Trends. 1998 Summer;(92):29-41
9679269
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Int Rev Psychiatry. 2003 Feb-May;15(1-2):65-73
12745312
Psychother Psychosom. 2003 Mar-Apr;72(2):71-9
12601224
Br J Psychiatry. 1997 Dec;171:556-60
9519096
BMJ. 2003 May 10;326(7397):1014
12742924
J Psychopharmacol. 2003 Dec;17(4):355-64
14870946
Br J Psychiatry. 2004 Nov;185:385-93
15516546
Stat Med. 2004 May 15;23(9):1351-75
15116347
Br J Psychiatry. 2000 May;176:421-8
10912216